Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
targeted AML1-ETO neoantigen cytotoxic T cells
- Development stage
- Phase 1
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Targeted AML1-ETO neoantigen cytotoxic T cells are a form of adoptive cell therapy in which patient-derived or donor-derived cytotoxic T lymphocytes (CTLs) are engineered or selected to specifically recognize and kill acute myeloid leukemia (AML) cells expressing the AML1-ETO fusion protein. This fusion protein results from the t(8;21)(q22;q22) chromosomal translocation, which is common in a subset of AML. The therapy exploits unique peptides (neoantigens) generated by the fusion event that are presented on the surface of leukemic blasts via major histocompatibility complex (MHC), allowing for highly specific targeting by infused CTLs. The mechanism involves direct recognition and lysis of leukemic cells harboring these antigens while sparing normal tissues. This approach is under clinical investigation for relapsed or refractory t(8;21)-positive acute myeloid leukemia[9][1].
- Other names
- AML1-ETO neoantigen-specific CTLAML-1-ETO neoantigen-specific CTLAML 1-ETO neoantigen-specific CTLtargeted AML1-ETO neoantigen CTLt(8;21) AML-targeted neoantigen cytotoxic T cells
02
Targets
AML1-ETO-pHLA (AML1-ETO-derived peptide-HLA complex)
Beyond the preview
Go deeper on targeted AML1-ETO neoantigen cytotoxic T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on targeted AML1-ETO neoantigen cytotoxic T cells.